Achillion Pharmaceuticals Inc (NASDAQ:ACHN) Shorts Strengthened By 7.64% As Of Dec 8, 2018

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Corporate Logo

During Q2 2018 the big money sentiment increased to 1.38. That’s change of 0.43, from 2018Q1’s 0.95. 11 investors sold all, 29 reduced holdings as Achillion Pharmaceuticals, Inc. ratio increased. 39 grew holdings while 16 funds acquired holdings. Funds hold 105.68 million shares thus 1.67% less from 2018Q1’s 107.48 million shares.
3.89M are held by Ecor1 Limited Co. Prudential has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Bancshares Of America Corp De has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Barclays Public Limited Co has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Gsa Cap Ptnrs Llp, a United Kingdom-based fund reported 243,369 shs. Connor Clark & Lunn Invest Management has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Bank & Trust Of New York Mellon invested 0% of its capital in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Teton Advsrs holds 10,000 shs or 0% of its capital. Ameriprise Fincl invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Pub Employees Retirement Association Of Colorado reported 0% stake. Rhumbline Advisers holds 0% of its capital in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 141,268 shs. Qs Invsts Limited Liability has invested 0.01% of its capital in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). State Board Of Administration Of Florida Retirement Systems reported 75,246 shs or 0% of all its holdings. Bb Biotech Ag invested in 0.1% or 1.28 million shs. Sg Americas Securities Limited Company has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) had an increase of its short interest by 7.64%. It was issued in December by FINRA the 6.14M short interest on ACHN. That’s 7.64% up from 5.70 million shares. Previous ACHN’s position will need 5 days to recover. It has 1.30M average volume. Achillion Pharmaceuticals Inc’s short interest float is 4.92%.

Ticker’s shares touched $3.11 during the last trading session after 0.64% change.Currently Achillion Pharmaceuticals, Inc. is downtrending after 11.53% change in last December 8, 2017. ACHN has also 1.20M shares volume. The stock underperformed the S&P500 by 27.15%.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally.The company has $431.10 million market cap. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial.Currently it has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

For more Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news published recently go to:,,, or The titles are as follows: “Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc. – Motley Fool” published on June 22, 2018, “Achillion Reports Third Quarter 2018 Financial Results Nasdaq:ACHN – GlobeNewswire” on November 07, 2018, “Achillion Appoints Dr. Steven Zelenkofske as Chief Medical Officer and Further Strengthens Clinical Development Team – GlobeNewswire” with a publish date: August 21, 2018, “Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 – Slideshow – Seeking Alpha” and the last “Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer – GlobeNewswire” with publication date: August 15, 2018.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.